Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
Abstract Pancreatic ductal adenocarcinoma (PDAC) responds poorly to systemic treatment, including new immunotherapeutic approaches. Biomarkers are urgently needed for early disease detection, patient stratification for treatment, and response prediction. The role of soluble CD40 (sCD40) is unknown i...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Portfolio
2023-10-01
|
| Saila: | npj Precision Oncology |
| Sarrera elektronikoa: | https://doi.org/10.1038/s41698-023-00459-9 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|